Evidence map›Paper›PMID 37691828›Full record

ReviewFrontiers in cell and developmental biology2023

Background and roles: myosin in autoimmune diseases.

Longsheng Fu, Yonghui Zou, Boyang Yu, Daojun Hong, Teng Guan, Jinfang Hu, Yi Xu, Yaoqi Wu, Junping Kou, Yanni Lv

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Longsheng FuDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Yonghui ZouDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Boyang YuJiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangxi, China.
Daojun HongDepartment of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Teng GuanDepartment of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada.
Jinfang HuDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Yi XuDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Yaoqi WuDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Junping KouJiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangxi, China.
Yanni LvDepartment of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
First Affiliated Hospital of Nanchang University · CNChina Pharmaceutical University · CNNanchang University · CNUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The myosin superfamily is a group of molecular motors. Autoimmune diseases are characterized by dysregulation or deficiency of the immune tolerance mechanism, resulting in an immune response to the human body itself. The link between myosin and autoimmune diseases is much more complex than scientists had hoped. Myosin itself immunization can induce experimental autoimmune diseases of animals, and myosins were abnormally expressed in a number of autoimmune diseases. Additionally, myosin takes part in the pathological process of multiple sclerosis, Alzheimer's disease, Parkinson's disease, autoimmune myocarditis, myositis, hemopathy, inclusion body diseases, etc. However, research on myosin and its involvement in the occurrence and development of diseases is still in its infancy, and the underlying pathological mechanisms are not well understood. We can reasonably predict that myosin might play a role in new treatments of autoimmune diseases.

Indexed as

Alzheimerautoimmuneautoimmune myocardioptismultiple sclerosismyosinNMMHC IIAParkinson

Identifiers

PMID37691828
PMCPMC10484797
OpenAlexW4386099544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.